Atazanavir / Cobicistat

U.S. Brand Name

Evotaz

Abbreviation(s)

ATV / COBI

First U.S. Approval

January 29, 2015

Component ARVs

NRTI Based?

No

One Dose Daily?

Yes

Single Tablet Regimen

No

U.S. FDA Label

U.S. Manufacturer

Bristol Myers Squibb

Other Reference Links

Clinical Info HIV Drug Database

National HIV Curriculum

Formulations

Strength	Formulation	Image	Description	Boosted
300 mg atazanavir + 150 mg cobicistat	Film-Coated Tablets	X	Pink, oval tablet with "3641" imprint on one side	Yes

Adult dosing

Dosage	Formulation	Population/Notes
1 tablet once daily	Film-Coated Tablets	Not recommended during pregnancy. Not recommended in patients with hepatic impairment. Monitor renal and hepatic function throughout treatment.

Pediatric dosing

film-coated, ≥ 35 kg, Same as adult in patients weighing 35 kg or more.

References

Displaying 1 - 6 of 6

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Atazanavir/cobicistat	Red: Avoid combination	Do not coadminister: increased levels of atazanavir	Potential for increased atazanavir adverse effects (e.g. hyperbilirubinemia, gastrointestinal effects).	AUC increased 321%; Cmax increased 560%	300/150 mg daily (fed state)	Not reported	Use alternative agents
Ritonavir ATV/c 1078	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Not studied		Not studied; Potential increased atazanavir levels)	Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
Tenofovir disoproxil fumarate ATV/c 729	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Potentially increased risk of TDF adverse effects and decreased efficacy of atazanavir	Not studied (may increase TDF levels)		Not studied (may decrease atazanavir levels)	If coadministering atazanavir, cobicistat, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg
Etravirine ATV/c 539	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied; Potential decreased atazanavir and cobicistat levels)	Use alternative agents
Efavirenz ATV/c 440	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied (may decrease atazanavir and cobicistat levels)	Use alternative agents
Maraviroc ATV/c 42	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce dose of maraviroc to 150 mg BID

Subscribe to Atazanavir / Cobicistat